MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has scheduled its first quarter 2025 financial results release for May 15, 2025, before market opening. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update.
Investors can access the conference call via dial-in numbers 646-307-1963 (New York) or 800-715-9871 (USA & Canada) using Conference ID 9822477. A live webcast and replay will be available through the company's investor relations website.
MiNK Therapeutics (NASDAQ: INKT), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie con cellule iNKT invariant, allogeniche e pronte all'uso, ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 per il 15 maggio 2025, prima dell'apertura dei mercati. La società terrà una conference call e una webcast alle 8:30 a.m. ET per discutere i risultati e fornire un aggiornamento aziendale.
Gli investitori potranno partecipare alla conference call chiamando i numeri 646-307-1963 (New York) o 800-715-9871 (USA e Canada) utilizzando il codice di accesso Conference ID 9822477. La diretta webcast e la registrazione saranno disponibili sul sito web delle relazioni con gli investitori dell'azienda.
MiNK Therapeutics (NASDAQ: INKT), una compañía biofarmacéutica en etapa clínica enfocada en el desarrollo de terapias con células iNKT invariantes, alogénicas y listas para usar, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el 15 de mayo de 2025, antes de la apertura del mercado. La compañía realizará una conferencia telefónica y una transmisión web a las 8:30 a.m. ET para discutir los resultados y proporcionar una actualización corporativa.
Los inversores podrán acceder a la conferencia telefónica marcando los números 646-307-1963 (Nueva York) o 800-715-9871 (EE.UU. y Canadá) usando el ID de conferencia 9822477. La transmisión en vivo y la repetición estarán disponibles en el sitio web de relaciones con inversionistas de la compañía.
MiNK Therapeutics (NASDAQ: INKT)는 동종 이식용, 즉시 사용 가능한 불변 자연 살해 T(iNKT) 세포 치료제를 개발하는 임상 단계의 생명공학 제약 회사로, 2025년 1분기 재무 결과 발표를 2025년 5월 15일 시장 개장 전으로 예정했습니다. 회사는 동부 표준시 오전 8시 30분에 결과를 논의하고 기업 업데이트를 제공하기 위해 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
투자자들은 646-307-1963 (뉴욕) 또는 800-715-9871 (미국 및 캐나다)로 전화하여 컨퍼런스 ID 9822477을 사용해 컨퍼런스 콜에 참여할 수 있습니다. 라이브 웹캐스트 및 녹화본은 회사 투자자 관계 웹사이트를 통해 제공됩니다.
MiNK Therapeutics (NASDAQ: INKT), une société biopharmaceutique en phase clinique spécialisée dans le développement de thérapies cellulaires iNKT invariantes allogéniques prêtes à l'emploi, a programmé la publication de ses résultats financiers du premier trimestre 2025 pour le 15 mai 2025, avant l'ouverture des marchés. La société organisera une conférence téléphonique et un webcast à 8h30 ET pour discuter des résultats et fournir une mise à jour d'entreprise.
Les investisseurs peuvent accéder à la conférence téléphonique en composant les numéros 646-307-1963 (New York) ou 800-715-9871 (États-Unis et Canada) en utilisant l'ID de conférence 9822477. Un webcast en direct et une rediffusion seront disponibles sur le site des relations investisseurs de la société.
MiNK Therapeutics (NASDAQ: INKT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung allogener, sofort verfügbarer, invarianten natürlichen Killer-T-Zelltherapien (iNKT) spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für den 15. Mai 2025 vor Börsenöffnung geplant. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz und Webcast veranstalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Investoren können die Telefonkonferenz über die Einwahlnummern 646-307-1963 (New York) oder 800-715-9871 (USA & Kanada) mit der Konferenz-ID 9822477 erreichen. Ein Live-Webcast und eine Aufzeichnung werden über die Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2025 financial results before the market opens on Thursday, May 15th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
Conference Call
Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada)
Conference ID: 9822477
Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/jgzwe9ny/.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
Media Contact
781-674-4428
communications@minktherapeutics.com
FAQ
When will MiNK Therapeutics (INKT) release Q1 2025 earnings?
How can I join MiNK Therapeutics (INKT) Q1 2025 earnings call?
What type of therapies does MiNK Therapeutics (INKT) develop?
Where can I find the webcast replay of INKT's Q1 2025 earnings call?
